Vantage Consulting Group’s TELA Bio TELA Stock Holding History

Vantage Consulting Group’s Portfolio TELA Stock Details TELA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-5,748	Closed	-$86K	–	1413
2020 Q4	$86K	Buy	+5,748	New	+$93.3K	0.01%	226

Other funds holding TELA

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vantage Consulting Group's TELA Position: Q1 2021 in Review

Vantage Consulting Group sold out of TELA Bio (TELA) in Q1 2021, closing a stake of 5,748 shares — an estimated $86K sold.

Vantage Consulting Group first reported a position in TELA in Q4 2020 and held it in 1 quarter. The position peaked at $86K in Q4 2020. 47 funds tracked by Wall St. Rank hold TELA as of Q1 2021.

Vantage Consulting Group reported no remaining TELA Bio position as of Q1 2021 after selling out during the quarter.
Vantage Consulting Group sold 5,748 TELA Bio shares in Q1 2021, an estimated $86K.
Vantage Consulting Group first reported a position in TELA Bio in Q4 2020 and held it in 1 quarter.
Vantage Consulting Group's TELA Bio position peaked at $86K in Q4 2020.
47 funds tracked by Wall St. Rank held TELA Bio as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.